Related Experiment Video
Updated: Jun 22, 2026

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
Published on: January 25, 2016
Sensorineural hearing loss in patients with cystic fibrosis
Alan G Cheng1, Patrick R Johnston, Jennifer Luz
1Department of Otolaryngology and Communication Enhancement, Children's Hospital Boston, and Department of Otology and Laryngology, Harvard Medical School, Boston, MA, USA. aglcheng@stanford.edu
Insights
Cystic fibrosis patients treated with aminoglycoside antibiotics face a high risk of developing sensorineural hearing loss (SNHL). Increased antibiotic courses correlate with a higher prevalence of SNHL in these patients.
Area of Science:
- Otolaryngology
- Pediatric Pulmonology
- Clinical Pharmacology
Background:
- Cystic fibrosis (CF) is a genetic disorder affecting multiple organs, including the auditory system.
- Sensorineural hearing loss (SNHL) is a potential complication in CF patients, possibly linked to treatments.
- Ototoxic medications, particularly aminoglycosides, are frequently used in CF management.
Purpose of the Study:
- To investigate the prevalence of SNHL in pediatric CF patients.
- To examine the association between SNHL and the cumulative use of potentially ototoxic antibiotics.
Main Methods:
- Retrospective case series utilizing chart review.
- Analysis of medical records from 50 CF patients at a tertiary care pediatric hospital (1994-2007).
- Data included demographics, audiometric/tympanometric results, CF genotype, and antibiotic exposure (aminoglycosides, macrolides).
Main Results:
- SNHL was identified in 14% (7/50) of CF patients.
- A significant correlation was found between SNHL and the number of intravenous aminoglycoside courses (>10 courses associated with 43% SNHL prevalence, P<0.01).
- Increased use of aminoglycosides via nasal irrigation (>5 courses associated with 23% SNHL prevalence, P<0.05) and macrolides (>5 courses associated with 60% SNHL prevalence, P=0.079) also showed trends towards higher SNHL risk.
Conclusions:
- CF patients receiving aminoglycoside antibiotics are at elevated risk for SNHL.
- Cumulative exposure to aminoglycosides, both intravenous and via nasal irrigation, is linked to increased SNHL incidence.
- Further research into ototoxicity monitoring and alternative therapies in CF is warranted.
Objective:
To determine the prevalence of sensorineural hearing loss (SNHL) in cystic fibrosis (CF) patients and its relationship to antibiotic use.
Study Design:
Case series with chart review.
Setting:
Tertiary care pediatric hospital.
Subjects And Methods:
We reviewed the medical records of CF patients seen in our children's hospital between March 1994 and December 2007. Data collected included patient demographics, audiograms, tympanograms, genotype, and use of potentially ototoxic antibiotics.
Results:
Seven of 50 (14%) patients had SNHL. Three percent of patients who received
Conclusion:
CF patients receiving aminoglycosides are at high risk for developing SNHL.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Unrenewable Cells
Photoreceptors
The retina is composed of several layers and contains specialized cells called photoreceptors. The photoreceptors (rods and cones) change their membrane potential when stimulated by light energy. There are two types of photoreceptors—rods and cones—which differ in the shape of their outer...
Cryptococcal Meningitis

